Literature DB >> 2203608

Retroviral proteinases.

S Oroszlan1, R B Luftig.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2203608     DOI： 10.1007/978-3-642-75218-6_6

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  73 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex.

Authors:  Etsuko Katoh; John M Louis; Toshimasa Yamazaki; Angela M Gronenborn; Dennis A Torchia; Rieko Ishima
Journal:  Protein Sci       Date:  2003-07       Impact factor: 6.725

4.  Export of a hyperexpressed mammalian globular cytochrome b5 precursor in Escherichia coli is dramatically affected by the nature of the amino acid flanking the secretory signal sequence cleavage bond.

Authors:  Naheed N Kaderbhai; Khalil Ahmed; Mustak A Kaderbhai
Journal:  Protein Sci       Date:  2010-07       Impact factor: 6.725

5.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

6.  A small region of the ecotropic murine leukemia virus (MuLV) gag gene profoundly influences the types of polytropic MuLVs generated in mice.

Authors:  M Lavignon; J Richardson; L H Evans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

Authors:  Jane M Sayer; John M Louis
Journal:  Proteins       Date:  2009-05-15

10.  Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly.

Authors:  R P Bennett; S Rhee; R C Craven; E Hunter; J W Wills
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.